keyword
MENU ▼
Read by QxMD icon Read
search

cinv

keyword
https://www.readbyqxmd.com/read/28427442/effect-of-acupuncture-in-prevention-and-treatment-of-chemotherapy-induced-nausea-and-vomiting-in-patients-with-advanced-cancer-study-protocol-for-a-randomized-controlled-trial
#1
Qi-Wei Li, Ming-Wei Yu, Guo-Wang Yang, Xiao-Min Wang, Huan Wang, Chen-Xi Zhang, Na Xue, Wei-Ru Xu, Qi Fu, Zhong Yang, Lin Yang
BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) is one of the most common and distressing side effects in patients with cancer. The introduction and development of antiemetic drugs have significantly improved the ability of clinicians to control CINV, but it is not easy to translate to practical application, owing to financial issues, provider-related barriers, and patient factors. Nondrug therapies are needed to alleviate the symptoms of CINV. Acupuncture is an appropriate adjunctive treatment for CINV, but additional evidence is needed...
April 20, 2017: Trials
https://www.readbyqxmd.com/read/28426542/the-preliminary-effects-of-massage-and-inhalation-aromatherapy-on-chemotherapy-induced-acute-nausea-and-vomiting-a-quasi-randomized-controlled-pilot-trial
#2
Pinar Zorba, Leyla Ozdemir
BACKGROUND: Despite pharmacological treatment, chemotherapy-induced nausea and vomiting (CINV) are observed in patients. OBJECTIVE: This quasi-randomized controlled pilot study evaluated the feasibility and preliminary effects of massage and inhalation aromatherapies on chemotherapy-induced acute nausea/vomiting. METHODS: Seventy-five patients with breast cancer were randomly grouped into 1 of 3 groups: massage (n = 25), inhalation (n = 25), and control (n = 25)...
April 20, 2017: Cancer Nursing
https://www.readbyqxmd.com/read/28398565/-identifying-predictive-factors-of-chemotherapy-induced-nausea-and-vomiting-cinv
#3
F Scotté
No abstract text is available yet for this article.
April 7, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28396308/new-options-and-controversies-in-the-management-of-chemotherapy-induced-nausea-and-vomiting
#4
Sara M Koth, Jill Kolesar
PURPOSE: An expanding array of options for prevention and treatment of chemotherapy-induced nausea and vomiting (CINV), including regimens containing olanzapine or recently approved neurokinin 1 (NK1) receptor antagonists, are reviewed. SUMMARY: Up to 80% of patients receiving chemotherapy have CINV. Current practice guidelines recommend that patients treated with highly emetogenic chemotherapy also receive a 3-drug antiemetic regimen initiated on the day of and continued for 3 days after chemotherapy administration, with the most commonly used 3-drug regimen consisting of an NK1 receptor antagonist, a 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist, and dexamethasone...
April 10, 2017: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/28395603/chemotherapy-induced-nausea-and-vomiting-cinv-in-190-colorectal-cancer-patients-a-prospective-registration-study-by-the-cinv-study-group-of-japan
#5
Yasushi Tsuji, Hideo Baba, Koji Takeda, Michiya Kobayashi, Eiji Oki, Masahiro Gotoh, Kazuhiro Yoshida, Mototsugu Shimokawa, Yoshihiro Kakeji, Keisuke Aiba
PURPOSE: Chemotherapy is an indispensable therapeutic approach for colorectal cancer both in the adjuvant and metastatic setting. Although chemotherapy-induced nausea and vomiting (CINV) is one of the most crucial adverse events, many aspects of CINV in patients with colorectal cancer remain unclear. METHODS: This multicenter, prospective, observational study analyzed the data of 190 colorectal cancer patients scheduled for moderately emetogenic chemotherapy (MEC)...
April 11, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28392826/nepa-a-new-fixed-combination-of-netupitant-and-palonosetron-is-a-cost-effective-intervention-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-the-uk
#6
REVIEW
Helene Cawston, Francois Bourhis, Jennifer Eriksson, Pierfrancesco Ruffo, Paolo D'Agostino, Marco Turini, Lee Schwartzberg, Alistair McGuire
BACKGROUND: The objective was to evaluate the cost-effectiveness of NEPA, an oral fixed combination netupitant (NETU, 300 mg) and palonosetron (PA, 0.5 mg) compared with aprepitant and palonosetron (APPA) or palonosetron (PA) alone, to prevent chemotherapy-induced nausea and vomiting (CINV) in patients undergoing treatment with highly or moderately emetogenic chemotherapy (HEC or MEC) in the UK. SCOPE: A systematic literature review and meta-analysis were undertaken to compare NEPA with currently recommended anti-emetics...
2017: Drugs in Context
https://www.readbyqxmd.com/read/28392676/differential-clinical-pharmacology-of-rolapitant-in-delayed-chemotherapy-induced-nausea-and-vomiting-cinv
#7
REVIEW
Noha Rashad, Omar Abdel-Rahman
Rolapitant is a highly selective neurokinin-1 receptor antagonist, orally administered for a single dose of 180 mg before chemotherapy with granisetron D1, dexamethasone 8 mg BID on day 2-4. It has a unique pharmacological characteristic of a long plasma half-life (between 163 and 183 hours); this long half-life makes a single use sufficient to cover the delayed emesis risk period. No major drug-drug interactions between rolapitant and dexamethasone or other cytochrome P450 inducers or inhibitors were observed...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28388860/chemotherapy-induced-nausea-and-vomiting-incidence-and-management-in-jordan
#8
Mohammad Al Qadire
Cancer patients experience a considerable number of symptoms during the course of their disease. Of these symptoms, chemotherapy-induced nausea and vomiting (CINV) is one of the most reported and it increases the cancer burden on patients. This study aims to assess the current status of CINV among Jordanian cancer patients, with regard to its incidence and management. A descriptive cross-sectional survey design was used. The study sample was 185 cancer patients. The mean age of participants was 46.6 years ( SD = 15...
April 1, 2017: Clinical Nursing Research
https://www.readbyqxmd.com/read/28376213/neurokinin-1-receptor-antagonist-based-triple-regimens-in-preventing-chemotherapy-induced-nausea-and-vomiting-a-network-meta-analysis
#9
Yaxiong Zhang, Yunpeng Yang, Zhonghan Zhang, Wenfeng Fang, Shiyang Kang, Youli Luo, Jin Sheng, Jianhua Zhan, Shaodong Hong, Yan Huang, Ningning Zhou, Hongyun Zhao, Li Zhang
Background: Neurokinin-1 receptor antagonists (NK-1RAs) are widely used for chemotherapy-induced nausea and vomiting (CINV) control in patients with highly emetogenic chemotherapy (HEC) and/or moderately emetogenic chemotherapy (MEC). Whether the efficacy and toxicity of antiemesis are different among various NK-1RA-based triple regimens is unknown. Methods: Data of complete responses (CRs) in the acute, delayed, and overall phases and treatment-related adverse events (TRAEs) were extracted from electronic databases...
February 1, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/28362229/late-chronotypes-are-associated-with-neoadjuvant-chemotherapy-induced-nausea-and-vomiting-in-women-with-breast-cancer
#10
Kwang-Min Lee, Doo-Young Jung, Heesung Hwang, Won-Hyoung Kim, Joo-Young Lee, Tae-Yong Kim, Seock-Ah Im, Kyung-Hun Lee, David Spiegel, Bong-Jin Hahm
Neoadjuvant chemotherapy, that is, the administration of chemotherapy before surgery, has been commonly used for locally advanced breast cancer to improve the surgical outcomes and increase the opportunity for breast-conserving therapy. Women with breast cancer often receive an anthracycline-based regimen as the neoadjuvant chemotherapy, which is associated with a high risk of emesis. Despite the development of novel antiemetics, chemotherapy-induced nausea and vomiting (CINV) has been commonly reported as a major adverse effect, affecting the quality of life of the patients...
2017: Chronobiology International
https://www.readbyqxmd.com/read/28349496/a-phase-ii-randomized-double-blind-placebo-controlled-study-of-6-gingerol-as-an-anti-emetic-in-solid-tumor-patients-receiving-moderately-to-highly-emetogenic-chemotherapy
#11
RANDOMIZED CONTROLLED TRIAL
J Konmun, K Danwilai, N Ngamphaiboon, B Sripanidkulchai, A Sookprasert, S Subongkot
6-Gingerol is a natural compound extracted from ginger. Preclinical studies demonstrated that 6-gingerol has an anti-emetic activity by inhibiting neurokinin-1, serotonin, and dopamine receptors. Several clinical trials examined crude ginger powder for preventing chemotherapy-induced nausea and vomiting (CINV), but none of them was conducted with a standardized bioactive compound. Patients who received moderately to highly emetogenic adjuvant chemotherapy were randomized to receive 6-gingerol 10 mg or placebo orally twice daily for 12 weeks...
April 2017: Medical Oncology
https://www.readbyqxmd.com/read/28333866/prevention-of-gastrointestinal-side-effects-in-paediatric-oncology-what-are-the-guidelines
#12
Karis K F Cheng
PURPOSE OF REVIEW: Gastrointestinal side-effects, particularly with regard to alimentary tract mucositis and chemotherapy-induced nausea and vomiting (CINV), continue to be frequent and debilitating symptomatic conditions among children and adolescents receiving cytotoxic cancer therapy. Further avenues of progress for mucositis and CINV prevention in paediatric oncology setting are warranted. RECENT FINDINGS: The current article reviews the major guidelines and literature published in 2016 pertaining to the prevention of mucositis and CINV...
March 22, 2017: Current Opinion in Supportive and Palliative Care
https://www.readbyqxmd.com/read/28325253/efficacy-and-safety-of-olanzapine-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting-a-systematic-review-and-meta-analysis
#13
REVIEW
Jukapun Yoodee, Unchalee Permsuwan, Mantiwee Nimworapan
BACKGROUND: Olanzapine is an anti-psychotic drug that has been used for preventing and treating Chemotherapy-Induced Nausea and Vomiting (CINV). This study aimed to systematically review and meta-analyze the efficacy and safety of olanzapine for prophylaxis and treatment of CINV. METHODS: We conducted a systematic literature search of MEDLINE, EMBASE, SCOPUS, and the Cochrane Central Register of Controlled Trials-CENTRAL up to July 15, 2016. All observational and intervention studies were included, but only the intervention studies were pooled for meta-analysis...
April 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28321977/the-relationship-between-hp-infection-and-vomiting-induced-by-gastrointestinal-cancer-chemotherapy
#14
Yiwei Yao, Chushu Ji, Yifu He, Yueyin Pan
BACKGROUND: Nausea and vomiting are the most common adverse reactions to chemotherapy. AIM: To discuss the relationship between Helicobacter pylori (HP) and chemotherapy-induced nausea and vomiting (CINV). METHODS: One hundred twelve patients with malignant tumours of the gastrointestinal tract were selected. Based on the 14C-urea breath test results, the patients were divided into HP-positive (n = 59) and HP-negative (n = 53) groups...
March 21, 2017: Internal Medicine Journal
https://www.readbyqxmd.com/read/28285236/efficacy-of-nepa-netupitant-palonosetron-across-multiple-cycles-of-chemotherapy-in-breast-cancer-patients-a-subanalysis-from-two-phase-iii-trials
#15
Hope S Rugo, Giorgia Rossi, Giada Rizzi, Matti Aapro
OBJECTIVES: Breast cancer (BC) patients represent a high-risk population for experiencing chemotherapy-induced nausea and vomiting (CINV), since they frequently receive highly emetogenic anthracycline-cyclophosphamide-based (AC) chemotherapy, and are often female and young, two predisposing risk factors for CINV. Guidelines recommend the combination of a neurokinin-1 receptor antagonist (NK1RA), 5-hydroxytryptamine-3 RA (5-HT3RA), and dexamethasone (DEX) for CINV prophylaxis in AC-treated patients...
March 9, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28260945/differential-pharmacology-and-clinical-utility-of-rolapitant-in-chemotherapy-induced-nausea-and-vomiting
#16
REVIEW
Bernardo Leon Rapoport
Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect of many cytotoxic chemotherapy regimens. CINV typically manifests during two well-defined time periods (acute and delayed phases). The acute phase is the first 24 hours after chemotherapy and is largely managed with 5-hydroxytryptamine 3 receptor antagonists. The delayed phase, a 5-day at-risk period during which patients are not often in direct contact with their health care provider, remains a significant unmet medical need. Neurokinin-1 (NK-1) receptor antagonists have demonstrated protection against acute and delayed CINV in patients treated with highly emetogenic chemotherapy and moderately emetogenic chemotherapy when used in combination with a 5-hydroxytryptamine 3 receptor antagonist and dexamethasone...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/28243404/effect-of-persian-medicine-remedy-on-chemotherapy-induced-nausea-and-vomiting-in-breast-cancer-a-double-blind-randomized-crossover-clinical-trial
#17
Mohammad Nazari, Ali Taghizadeh, Mojtaba Mousavi Bazzaz, Hassan Rakhshandeh, Sadegh Shokri
BACKGROUND: Chemotherapy induced nausea and vomiting (CINV) is a side effect, and has negative effect on quality of life and continuation of chemotherapy. Despite new regimen and drugs, the problems still remain and standard guidelines, effective treatment and supportive care for refractory CINV are still not yet established. Persian medicine, the old Iranian medical school, offer Persumac (prepared from Rhus Coriaria and Bunium Persicum Boiss). OBJECTIVE: The specific objectives were to assess the effect of Persumac on the number and severity of nausea and vomiting in refractory CINV in acute and delayed phase...
January 2017: Electronic Physician
https://www.readbyqxmd.com/read/28235999/concise-review-of-the-management-of-iatrogenic-emesis-using-cannabinoids-emphasis-on-nabilone-for-chemotherapy-induced-nausea-and-vomiting
#18
REVIEW
Joseph V Pergolizzi, Robert Taylor, Jo Ann LeQuang, Gianpietro Zampogna, Robert B Raffa
Chemotherapy-induced nausea and vomiting (CINV) is a prevalent, distressing, and burdensome side effect of cancer chemotherapy. It is estimated to affect the majority of patients receiving certain anti-cancer drug regimens and can be treatment-limiting, even for life-saving medications. Despite seemingly numerous options, such as antimuscarinic anticholinergics, antihistamines, 5-HT3 receptor antagonists, dopamine receptor antagonists, and neurokinin-1 receptor antagonists, preventative therapies are often inadequately effective, particularly for "delayed CINV"-leaving an important unmet clinical need...
March 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28217830/relationship-between-alcohol-metabolism-and-chemotherapy-induced-emetic-events-in-breast-cancer-patients
#19
Toshitaka Uomori, Yoshiya Horimoto, Kaoru Mogushi, Joe Matsuoka, Mitsue Saito
BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) can negatively affect quality of life and treatment compliance in breast cancer patients. Habitual alcohol consumption reportedly shows an inverse correlation with CINV, though the underlying mechanism is unknown. Acetaldehyde dehydrogenase 2 (ALDH2), one of the two ALDH isozymes, is reportedly the major factor among several genetic polymorphisms possibly affecting alcohol metabolism. More than 40% of Japanese have ALDH2 mutations, while almost all Westerners have the wild type...
February 20, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/28194109/delayed-chemotherapy-induced-nausea-and-vomiting-pathogenesis-incidence-and-current-management
#20
REVIEW
Bernardo L Rapoport
Even when chemotherapy-induced nausea and vomiting (CINV) can be effectively controlled in the acute phase, it may still occur in the delayed phase. Identifying at-risk patients is complex and requires consideration of clinical, personal, demographic, and behavioral factors. Delayed CINV has a significant detrimental effect on patients' daily life and is responsible for significant healthcare resource utilization. Patients who do not experience acute CINV are not necessarily exempt from delayed CINV, and healthcare professionals have been shown to underestimate the incidence of delayed CINV...
2017: Frontiers in Pharmacology
keyword
keyword
28477
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"